Status:
COMPLETED
To Investigate Genetic Factors Associated With the Response to Anti-TNF Therapy in Patients With Early AS
Lead Sponsor:
Sun Yat-sen University
Collaborating Sponsors:
Pfizer
Conditions:
Ankylosing Spondylitis
Eligibility:
All Genders
18-65 years
Brief Summary
Ankylosing spondylitits (AS) is a chronic, systemic rheumatic disease primarily affecting spine and sacroiliac joints, which belongs to the group of conditions known as spondyloarthopathies and causes...
Eligibility Criteria
Inclusion
- Fulfilled ASAS2009 criterioncriteria; 2.The duration of axial syptoms less than 2 years and in active status before treatment(BASDAI≥4）；3.HLA-B27 positive；4.Completed the Etanercept treatment of 12-24 weeks;5. Completed the clinical data and questionnaire rbefore and after of the treatment; 6. Assigend the ICF.
Exclusion
- Received other anti-TNF-αagents treatment; 2.Patients with other rheumatic disease which may influent gene test and efficacy, including RA, PsA, OA, SLE, etc. 3.Other possible influence factors , including articular cavity local injections of glucocorticoid prior 4 weeks before TNF alpha antagonists treatment;4. Incomplete data.
- \-
Key Trial Info
Start Date :
January 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT02311842
Start Date
January 1 2012
End Date
December 1 2013
Last Update
December 8 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Rheumatology, the Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China